Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report).
Date of Report: March 28, 2014.
Reporting Period: The filing reports results of operations for the quarter and full year ended December 31, 2013.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not contain specific numerical values for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Margins
- Debt or Liquidity positions
Conclusion: The filing text does not provide a clear value for any specific financial metric; these figures are contained in the attached Exhibit 99.1 which is not included in the input.
Material Changes
The filing announces the release of financial results for the period ended December 31, 2013. No specific material changes, percentage growth, or declines are detailed in the provided text.
Guidance, Outlook, and Risks
Management Commentary: The filing states that results were reported on March 28, 2014, via a press release.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Guidance/Risks: The provided text does not contain specific forward-looking guidance, risk factors, or details on contingencies.
Investor Verification Checklist
- Verify the correct registrant name (RXi Pharmaceuticals Corporation vs. Phio Pharmaceuticals Corp.) to ensure accurate historical data retrieval.
- Locate and review Exhibit 99.1 (Press Release dated March 28, 2014) to obtain actual revenue, net loss, and cash position figures.
- Confirm the specific operational milestones or clinical trial updates mentioned in the full press release, as the 8-K text only references their existence.